加载中...

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

170 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Optimizing Hypertension Management Through Remote Monitoring: Insights from a Randomized Controlled Trial

Optimizing Hypertension Management Through Remote Monitoring: Insights from a Randomized Controlled Trial

This study demonstrates the superior effectiveness of remote monitoring in reducing blood pressure among hypertensive patients compared to usual care and self-monitoring.

Section: CardiologyOct 3, 2025

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction

The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.

Section: CardiologyOct 3, 2025

Lorundrostat: A New Frontier in the Management of Uncontrolled and Treatment-Resistant Hypertension

Lorundrostat: A New Frontier in the Management of Uncontrolled and Treatment-Resistant Hypertension

Lorundrostat, an aldosterone synthase inhibitor, significantly reduced systolic blood pressure in adults with uncontrolled and treatment-resistant hypertension, demonstrating efficacy and safety as an adjunct therapy.

Section: CardiologyOct 2, 2025

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.

Section: Clinical UpdatesOct 2, 2025

Ashwagandha Supplementation for Cognitive Enhancement: Evidence from MCI and Healthy Populations

Ashwagandha Supplementation for Cognitive Enhancement: Evidence from MCI and Healthy Populations

Recent randomized trials show ashwagandha, including Somin-On™, significantly improves memory and cognitive function in adults with mild cognitive impairment and healthy young adults, with good safety profiles.

Section: Clinical UpdatesOct 2, 2025

Pomegranate Peel Extract: A Promising Adjunct in Non-Alcoholic Fatty Liver Disease Management?

Pomegranate Peel Extract: A Promising Adjunct in Non-Alcoholic Fatty Liver Disease Management?

A double-blind RCT suggests pomegranate peel extract may improve liver enzymes, lipid profile, and inflammation in NAFLD patients, but does not significantly alter liver steatosis grade.

Section: Clinical UpdatesOct 2, 2025

Flaxseed Powder Supplementation: Emerging Evidence in Non-Alcoholic Fatty Liver Disease and Metabolic Health

Flaxseed Powder Supplementation: Emerging Evidence in Non-Alcoholic Fatty Liver Disease and Metabolic Health

Flaxseed powder supplementation shows promise in improving liver fat, lipid metabolism, and inflammation in NAFLD and related metabolic disorders, with effects on gut microbiota but limited synergism with fasting mimicking diets.

Section: Diabetes & EndocrinologyOct 2, 2025

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timin

Section: Clinical UpdatesOct 2, 2025

Intermittent Fasting for Weight Loss in Night Shift Workers: A Three-Arm Superiority Randomised Clinical Trial

Intermittent Fasting for Weight Loss in Night Shift Workers: A Three-Arm Superiority Randomised Clinical Trial

This clinical trial compared two modified intermittent fasting strategies to continuous energy restriction for weight loss and insulin resistance improvements in night shift workers, finding no significant differences but overall health ben

Section: Clinical UpdatesOct 2, 2025

Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial

Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial

A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.

Section: Clinical UpdatesOct 2, 2025

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.

Section: Clinical UpdatesOct 2, 2025

Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?

Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?

A phase II trial finds that intrathecal autologous bone marrow mononuclear cell therapy combined with education significantly improves core symptoms and adaptive behaviors in young children with ASD compared to education alone.

Section: Clinical UpdatesOct 2, 2025

$Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial$

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.

Section: Clinical UpdatesOct 2, 2025

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.

Section: Clinical UpdatesOct 2, 2025

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Section: Clinical UpdatesOct 2, 2025

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Section: Clinical UpdatesOct 2, 2025

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Section: Clinical UpdatesOct 2, 2025

Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial

Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial

A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po

Section: Hematology-OncologyOct 2, 2025

Testosterone Therapy in Middle-Aged and Older Men with Hypogonadism: Balancing Clinical Benefits and Risks

Testosterone Therapy in Middle-Aged and Older Men with Hypogonadism: Balancing Clinical Benefits and Risks

Testosterone therapy offers modest benefits for sexual function, anemia, and bone health in older men with hypogonadism, but increases risks of venous thromboembolism, fractures, and arrhythmias. Careful patient selection and individualized

Section: Clinical UpdatesOct 2, 2025

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and

Section: Clinical UpdatesOct 1, 2025

Prev 1 5 6 7 8 9 Next